Patent 10519127 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: